Tirzepatide Dosing
Tirzepatide is initiated at 2.5 mg subcutaneously once weekly and titrated monthly by 2.5 mg increments to a maximum dose of 15 mg weekly, with FDA-approved maintenance doses of 5 mg, 10 mg, or 15 mg for both obesity and type 2 diabetes. 1
Standard Titration Schedule
The recommended dose escalation follows a structured monthly progression 1:
- Week 0-4: 2.5 mg once weekly (starting dose)
- Week 5-8: 5 mg once weekly
- Week 9-12: 7.5 mg once weekly
- Week 13-16: 10 mg once weekly
- Week 17-20: 12.5 mg once weekly
- Week 21+: 15 mg once weekly (maximum dose)
The monthly titration schedule is critical for tolerability. Research demonstrates that slower dose escalation with smaller increments significantly reduces gastrointestinal side effects compared to more aggressive titration 2. The half-life of approximately 5 days (116.7 hours) supports once-weekly dosing 1, 3.
Contraindications
Absolute contraindications include:
- Personal or family history of medullary thyroid carcinoma 4, 5
- Multiple endocrine neoplasia syndrome type 2 4, 5
- Pregnancy and breastfeeding 4
Use extreme caution or avoid in:
Renal Impairment Dose Adjustments
No dose adjustment is required for any degree of renal impairment, including end-stage kidney disease. 6, 7, 8
This represents a significant advantage over many other glucose-lowering agents. Tirzepatide undergoes proteolytic degradation rather than renal excretion, making it safe across all levels of kidney function 7. The 2022 KDIGO/ADA consensus specifically notes that GLP-1 receptor agonists like tirzepatide require no dose adjustment even in advanced CKD 8.
Key monitoring considerations in renal impairment:
- Monitor kidney function when initiating or escalating doses, particularly if gastrointestinal side effects occur 7, 8
- Severe gastrointestinal reactions (vomiting, diarrhea) can lead to volume depletion and acute kidney injury 9
- One case report documented AKI after rapid dose escalation in a patient with multiple comorbidities and polypharmacy, emphasizing the importance of standard titration schedules 9
Hepatic Impairment Dose Adjustments
No dose adjustment is required for any degree of hepatic impairment, including severe (Child-Pugh C) cirrhosis. 10
A dedicated pharmacokinetic study demonstrated that tirzepatide exposure (AUC and Cmax) was similar across all degrees of hepatic impairment compared to healthy controls 10. The 90% confidence intervals for exposure ratios all spanned unity, confirming no clinically relevant differences. This is because tirzepatide undergoes proteolytic degradation rather than hepatic metabolism 10.
Clinical Efficacy Context
The dosing strategy is supported by robust efficacy data:
- For obesity: 15 mg achieved 22.5% weight reduction at 72 weeks in SURMOUNT-1 1
- For type 2 diabetes with obesity: 10-15 mg achieved 12.8-14.7% weight reduction and 2.2% HbA1c reduction in SURMOUNT-2 1
- For type 2 diabetes: All doses (5-15 mg) achieved 1.9-2% HbA1c reduction with >87% reaching HbA1c <7% 1
Common Pitfalls to Avoid
Rapid dose escalation: Accelerating beyond monthly increases significantly increases nausea and vomiting risk 2, 9
Inadequate monitoring during dose escalation: The highest risk period for gastrointestinal side effects is during dose increases 1. Monitor for dehydration, particularly in patients on diuretics or with renal impairment 9.
Unnecessary dose reductions for renal/hepatic impairment: Unlike many medications, tirzepatide requires no adjustment 6, 7, 10
Premature discontinuation: Most gastrointestinal side effects are mild-to-moderate and resolve spontaneously 1, 11. Only 4.3-7.1% discontinued in trials due to adverse events 11.
Ignoring polypharmacy interactions: In patients on multiple antihypertensives or diuretics, volume depletion from gastrointestinal effects can precipitate hemodynamic complications 9
Long-Term Maintenance
Continuing tirzepatide at maximum tolerated dose is superior to dose reduction or discontinuation for maintaining weight loss. Recent data from SURMOUNT-MAINTAIN showed that continuing at maximum tolerated dose (10-15 mg) maintained 21.9% weight reduction at 112 weeks, while reducing to 5 mg resulted in 16.6% reduction, and placebo resulted in only 9.9% reduction 12. This emphasizes that obesity requires ongoing pharmacotherapy for sustained benefit.